Company

Rivermark Medical, Inc.

Rivermark Medical develops minimally invasive devices to treat benign prostatic hyperplasia.

About

Founded in 2021 in Wisconsin, Rivermark Medical develops devices for treating benign prostatic hyperplasia. Its FloStent System is designed to restore urinary function through a minimally invasive procedure. In May 2026, the company raised USD 20 million in series D funding led by Andera Partners, with participation from Cadence Healthcare Ventures, View Ventures, Anduril Ventures GmbH, American Century Investments, Venture Investors, Time BioVentures, and other unspecified investors.

4Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in